Key Drivers
- Strong Returns
- Rising Leverage
- Rich Valuation
AIAI Summary
CSL should now be viewed as a premium healthcare franchise under an execution test: the FY26 revenue reset must prove temporary, with the next result needing to confirm stable margins and cash conversion before the market re-rates the stock, while any repeat slowdown would pressure an already expensive valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Returns
- •Rising Leverage
- •Rich Valuation
CSL delivers high-quality earnings, strong returns and solid cash generation, but rising leverage, thinner cash reserves and a rich valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •$360 support
- •$390 resistance
CSL remains in an uptrend after recovering from the low-$320s to $370.04 last month, but the recent pullback from near $390 shows near-term resistance and consolidation above the $360 support zone.
Three straight down sessions after a near-$390 high signaled short-term momentum cooling
Sentiment & News
Key News Insights:
- •Record quarter
- •Capital returns
- •Efficiency focus
Carlisle Companies delivered record Q2 results, raised 2026 guidance, and stepped up buybacks and dividends, while CSL advanced a new manufacturing process trial aimed at boosting plasma output.
The news is broadly positive for Carlisle Companies and supportive for CSL, highlighting stronger execution, shareholder returns, and capacity-led growth initiatives
Similar Companies in Industrials
Other companies in the same sector with AI ratings